AXSM Quote, Financials, Valuation and Earnings

Fortress Biotech, Inc. has a net margin of -27.62% compared to Axsome Therapeutics, Inc.'s net margin of 50.07%. Axsome Therapeutics, Inc.'s return on equity of -327.97% beat Fortress Biotech, Inc.'s return on equity of -223.06%.

Axsome Therapeutics, Inc. has a consensus price target of $181.31, signalling upside risk potential of 21.6%. On the other hand Fortress Biotech, Inc. has an analysts' consensus of $10.75 which suggests that it could grow by 299.63%. Given that Fortress Biotech, Inc. has higher upside potential than Axsome Therapeutics, Inc., analysts believe Fortress Biotech, Inc. is more attractive than Axsome Therapeutics, Inc..

Axsome Therapeutics, Inc. has a beta of 0.476, which suggesting that the stock is 52.416% less volatile than S&P 500. In comparison Fortress Biotech, Inc. has a beta of 1.490, suggesting its more volatile than the S&P 500 by 49.031%.

Axsome Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics, Inc. pays -- of its earnings as a dividend. Fortress Biotech, Inc. pays out 3.9% of its earnings as a dividend. Fortress Biotech, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Axsome Therapeutics, Inc. quarterly revenues are $171M, which are larger than Fortress Biotech, Inc. quarterly revenues of $17.6M. Axsome Therapeutics, Inc.'s net income of -$47.2M is lower than Fortress Biotech, Inc.'s net income of $8.8M. Notably, Axsome Therapeutics, Inc.'s price-to-earnings ratio is -- while Fortress Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics, Inc. is 12.96x versus 1.27x for Fortress Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -27.62% compared to Axsome Therapeutics, Inc.'s net margin of 38.89%. Axsome Therapeutics, Inc.'s return on equity of -327.97% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Axsome Therapeutics, Inc. has a consensus price target of $181.31, signalling upside risk potential of 21.6%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $768.36 which suggests that it could grow by 6.18%. Given that Axsome Therapeutics, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Axsome Therapeutics, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Axsome Therapeutics, Inc. has a beta of 0.476, which suggesting that the stock is 52.416% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.

Axsome Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.49% to investors and pays a quarterly dividend of $0.88 per share. Axsome Therapeutics, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Axsome Therapeutics, Inc. quarterly revenues are $171M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Axsome Therapeutics, Inc.'s net income of -$47.2M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Axsome Therapeutics, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics, Inc. is 12.96x versus 5.60x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics, Inc. has a net margin of -27.62% compared to Axsome Therapeutics, Inc.'s net margin of 19.97%. Axsome Therapeutics, Inc.'s return on equity of -327.97% beat TG Therapeutics, Inc.'s return on equity of 145.71%.

Axsome Therapeutics, Inc. has a consensus price target of $181.31, signalling upside risk potential of 21.6%. On the other hand TG Therapeutics, Inc. has an analysts' consensus of $44.29 which suggests that it could grow by 40.1%. Given that TG Therapeutics, Inc. has higher upside potential than Axsome Therapeutics, Inc., analysts believe TG Therapeutics, Inc. is more attractive than Axsome Therapeutics, Inc..

Axsome Therapeutics, Inc. has a beta of 0.476, which suggesting that the stock is 52.416% less volatile than S&P 500. In comparison TG Therapeutics, Inc. has a beta of 2.014, suggesting its more volatile than the S&P 500 by 101.386%.

Axsome Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics, Inc. pays -- of its earnings as a dividend. TG Therapeutics, Inc. pays out -- of its earnings as a dividend.

Axsome Therapeutics, Inc. quarterly revenues are $171M, which are larger than TG Therapeutics, Inc. quarterly revenues of $161.7M. Axsome Therapeutics, Inc.'s net income of -$47.2M is lower than TG Therapeutics, Inc.'s net income of $390.9M. Notably, Axsome Therapeutics, Inc.'s price-to-earnings ratio is -- while TG Therapeutics, Inc.'s PE ratio is 11.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics, Inc. is 12.96x versus 9.61x for TG Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics, Inc. has a net margin of -27.62% compared to Axsome Therapeutics, Inc.'s net margin of --. Axsome Therapeutics, Inc.'s return on equity of -327.97% beat Viking Therapeutics, Inc.'s return on equity of -28.62%.

Axsome Therapeutics, Inc. has a consensus price target of $181.31, signalling upside risk potential of 21.6%. On the other hand Viking Therapeutics, Inc. has an analysts' consensus of $93.39 which suggests that it could grow by 163.74%. Given that Viking Therapeutics, Inc. has higher upside potential than Axsome Therapeutics, Inc., analysts believe Viking Therapeutics, Inc. is more attractive than Axsome Therapeutics, Inc..

Axsome Therapeutics, Inc. has a beta of 0.476, which suggesting that the stock is 52.416% less volatile than S&P 500. In comparison Viking Therapeutics, Inc. has a beta of 0.649, suggesting its less volatile than the S&P 500 by 35.072%.

Axsome Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics, Inc. pays -- of its earnings as a dividend. Viking Therapeutics, Inc. pays out -- of its earnings as a dividend.

Axsome Therapeutics, Inc. quarterly revenues are $171M, which are larger than Viking Therapeutics, Inc. quarterly revenues of --. Axsome Therapeutics, Inc.'s net income of -$47.2M is higher than Viking Therapeutics, Inc.'s net income of -$90.8M. Notably, Axsome Therapeutics, Inc.'s price-to-earnings ratio is -- while Viking Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics, Inc. is 12.96x versus -- for Viking Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.